FDA Approves Pralsetinib for RET+ Thyroid Cancers

December 01, 2020

The FDA approved pralsetinib for the treatment of adult and pediatric patients who are 12 years old or older with advanced or metastatic RET-mutant medullary thyroid cancer and require systemic therapy.

Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL

December 01, 2020

During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.

FDA Grants Fast Track Designation to Onivyde in Small Cell Lung Cancer

December 01, 2020

The FDA has granted a Fast Track designation to the irinotecan liposome injection as a potential treatment option for patients with small cell lung cancer who progressed following a first-line platinum-based regimen, Ipsen announced, in a press release.

Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022

December 01, 2020

The MET inhibitor TPX-0022 was safe and well tolerated in a phase 1 dose-escalation study, SHIELD-1, involving patients with advanced solid tumors harboring MET alterations, according to results presented during the 32nd Molecular Targets and Cancer Therapeutics Symposium.

FDA Grants Priority Review to Belumosudil for Chronic Graft-Versus-Host Disease

November 30, 2020

The FDA accepted the New Drug Application from belumosudil and granted it a Priority Review designation for the treatment of patients with chronic graft-versus-host disease. The Prescription Drug User Fee Act target action date has been set to May 30, 2021.